BioWorld

June 19, 2006

Mining Minds Of Doctors For Better Predicting Drug Market

Sangamo Stock Sale Raises $20M For Zinc-Finger Efforts

Other News To Note

Neurocrine Shares Slide On Likely Indiplon Delay

The long-anticipated sleep drug indiplon probably will need further studies in the wake of recent approvable and not-approvable letters from the FDA. (BioWorld Today) Read More

VLST Brings In $20M Via First Tranche Of Series B

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...